Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine
Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine
BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing
BroadOak portfolio company PBS Biotech, an innovative manufacturer of single-use bioreactors, has completed a $22 million
BroadOak portfolio company PhenoVista Biosciences, a leading provider of both custom and off-the-shelf imaging-based assay services,
BioCare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization)
BroadOak partnered with United BioChannels (UBC) to acquire ORFLO Technologies (ORFLO) in October 2022. ORFLO, a
Flagship Biosciences hired industry veteran Tom Turi as Chief Scientific Officer. Tom will help grow the
BroadOak completed a growth equity investment in EmVenio Research, alongside members of the company’s management team
Following BroadOak’s growth equity investment in Flagship Biosciences, Flagship Biosciences has acquired Interpace Pharma Solutions, a
It is an exciting time at BroadOak as we help advance innovative life sciences technologies.
Holly Atallah
Director of Finance & Operations
BroadOak has advised and invested in life sciences companies for over 15 years. Get to know us.